[{"orgOrder":0,"company":"University of California, Irvine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Neostigmine","moa":"Acetylcholinesterase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of California, Irvine \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of California, Irvine \/ Merck & Co"},{"orgOrder":0,"company":"Myungmoon Pharm. Co., LTD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Chenodeoxycholic Acid","moa":"Bile acid receptor FXR","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Myungmoon Pharm. Co., LTD.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myungmoon Pharm. Co., LTD. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Myungmoon Pharm. Co., LTD. \/ Undisclosed"},{"orgOrder":0,"company":"Prisma Health-Upstate","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methocarbamol","moa":"Carbonic anhydrase I","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Prisma Health-Upstate","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prisma Health-Upstate \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Prisma Health-Upstate \/ Undisclosed"},{"orgOrder":0,"company":"Pharmbio Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Oral Sulfate","moa":"Colon","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Pharmbio Korea","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmbio Korea \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pharmbio Korea \/ Undisclosed"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Benzydamine Hydrochloride","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Angelini Pharma \/ PPD","highestDevelopmentStatusID":"11","companyTruncated":"Angelini Pharma \/ PPD"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"PROCTER AND GAMBLE","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bismuth Subsalicylate","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"University of Cincinnati \/ PROCTER AND GAMBLE","highestDevelopmentStatusID":"11","companyTruncated":"University of Cincinnati \/ PROCTER AND GAMBLE"},{"orgOrder":0,"company":"mohamed bouchoucha","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"mohamed bouchoucha","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"mohamed bouchoucha \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"mohamed bouchoucha \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Ferass Abu Hanna","sponsor":"Ambrosia - SupHerb Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Ferass Abu Hanna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferass Abu Hanna \/ Ambrosia - SupHerb Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Ferass Abu Hanna \/ Ambrosia - SupHerb Ltd."},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Risankizumab","moa":"Interleukin-23","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"Regeneron Pharmaceuticals | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of North Carolina \/ Regeneron Pharmaceuticals | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina \/ Regeneron Pharmaceuticals | Sanofi"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, San Diego \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Diego \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Regeneron Pharmaceuticals | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Regeneron Pharmaceuticals | Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Children's Hospital of Philadelphia \/ Regeneron Pharmaceuticals | Sanofi"},{"orgOrder":0,"company":"International University of Health and Welfare","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Naldemedine","moa":"Mu opioid receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"International University of Health and Welfare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"International University of Health and Welfare \/ Shionogi","highestDevelopmentStatusID":"11","companyTruncated":"International University of Health and Welfare \/ Shionogi"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rebamipide","moa":"N-formyl peptide receptor (FPR1)","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Stryker","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Health Network, Toronto \/ Stryker","highestDevelopmentStatusID":"11","companyTruncated":"University Health Network, Toronto \/ Stryker"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Carnot Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Carnot Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Carnot Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Carnot Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Oregon Health and Science University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Oregon Health and Science University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oregon Health and Science University \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Oregon Health and Science University \/ Merck & Co"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Granisetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Yung Shin Pharm Industrial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palonosetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Yung Shin Pharm Industrial","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yung Shin Pharm Industrial \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Yung Shin Pharm Industrial \/ Undisclosed"},{"orgOrder":0,"company":"Kyle Staller","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Kyle Staller","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kyle Staller \/ Ardelyx","highestDevelopmentStatusID":"11","companyTruncated":"Kyle Staller \/ Ardelyx"},{"orgOrder":0,"company":"Belgian Inflammatory Bowel Disease Research and Development","sponsor":"Celltrion","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Belgian Inflammatory Bowel Disease Research and Development","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Belgian Inflammatory Bowel Disease Research and Development \/ Celltrion","highestDevelopmentStatusID":"11","companyTruncated":"Belgian Inflammatory Bowel Disease Research and Development \/ Celltrion"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"European Crohn\u00b4s and Colitis Organisation | B\u00fchlmann Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"TNF-alpha","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ European Crohn\u00b4s and Colitis Organisation | B\u00fchlmann Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"University Medical Center Groningen \/ European Crohn\u00b4s and Colitis Organisation | B\u00fchlmann Laboratories"},{"orgOrder":0,"company":"David Binion, MD","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bezlotoxumab","moa":"Toxin B","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"David Binion, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"David Binion, MD \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"David Binion, MD \/ Merck & Co"},{"orgOrder":0,"company":"EP Plus Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MALAYSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Skal Pro","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"EP Plus Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"EP Plus Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"EP Plus Group \/ Undisclosed"},{"orgOrder":0,"company":"Arcadia Consumer Healthcare","sponsor":"Stony Brook University","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorine Dioxide","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Arcadia Consumer Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcadia Consumer Healthcare \/ Stony Brook University","highestDevelopmentStatusID":"11","companyTruncated":"Arcadia Consumer Healthcare \/ Stony Brook University"},{"orgOrder":0,"company":"Aalborg University","sponsor":"Regionshospital Nordjylland | Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Citrafleet","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Aalborg University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aalborg University \/ Regionshospital Nordjylland | Norgine","highestDevelopmentStatusID":"11","companyTruncated":"Aalborg University \/ Regionshospital Nordjylland | Norgine"},{"orgOrder":0,"company":"Myungmoon Pharm. Co., LTD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CnU","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Myungmoon Pharm. Co., LTD.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Myungmoon Pharm. Co., LTD. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Myungmoon Pharm. Co., LTD. \/ Undisclosed"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Xi'an Beilin Pharmaceutical Co. Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Jinsang Liyan","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tongji Hospital \/ Xi'an Beilin Pharmaceutical Co. Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Tongji Hospital \/ Xi'an Beilin Pharmaceutical Co. Ltd"},{"orgOrder":0,"company":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","sponsor":"Atabay","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Neoven 225","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey \/ Atabay","highestDevelopmentStatusID":"11","companyTruncated":"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey \/ Atabay"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Zoster Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"University of Wisconsin, Madison \/ GSK"},{"orgOrder":0,"company":"St. Joseph's Health, New York","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Senna","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"St. Joseph's Health, New York","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"St. Joseph's Health, New York \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"St. Joseph's Health, New York \/ Undisclosed"},{"orgOrder":0,"company":"Vibrant Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Vibrant Ltd.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vibrant Ltd. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Vibrant Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"HONG KONG","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irsogladine Maleate","moa":"Gap junctions\/Unknown","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Inflammatory Bowel Diseases.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          April 04, 2024

                          Lead Product(s) : Risankizumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          02

                          Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Eosinophilic Esophagitis.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          October 25, 2023

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Neoven 225 is a Dietary Supplement drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Hemorrhoids.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          August 19, 2025

                          Lead Product(s) : Neoven 225

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Atabay

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          International University of Health and Welfare

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          International University of Health and Welfare

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Naldemedine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Opioid-Induced Constipation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 26, 2025

                          Lead Product(s) : Naldemedine

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Shionogi

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : CnU is a drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Dyspepsia.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 11, 2025

                          Lead Product(s) : CnU

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharma MES 2025
                          Not Confirmed
                          Pharma MES 2025
                          Not Confirmed

                          Details : Chenodeoxycholic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Cholelithiasis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 05, 2025

                          Lead Product(s) : Chenodeoxycholic Acid

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Carnot Laboratories

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Carnot Laboratories

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Tegoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Gastroesophageal Reflux.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 27, 2025

                          Lead Product(s) : Tegoprazan

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Ferass Abu Hanna

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Ferass Abu Hanna

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : This is a Probiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Constipation.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          May 07, 2025

                          Lead Product(s) : Probiotic

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Ambrosia - SupHerb Ltd.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          St. Joseph's Health, New York

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          St. Joseph's Health, New York

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Senna is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Constipation.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          February 13, 2025

                          Lead Product(s) : Senna

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          University of California, San Diego

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          University of California, San Diego

                          Country arrow
                          Pharma MES 2025
                          Not Confirmed

                          Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Eosinophilic Esophagitis.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          October 30, 2024

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase IV

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank